Patent ID: 9221751
Filing Date: 2015-12-29
Classification: A61K,C07C

Abstract:
1. A method for the treatment of a liver fibrosis or of a non-alcoholic fatty liver disease in a subject in need thereof, comprising administering to the subject a compound of General Formula (I) in which: X1 represents a halogen, a R1, or G1-R1 group; A represents a CH═CH or a CH2-CH2 group; X2 represents a G2-R2 group; G1 and G2, identical or different, represent an atom of oxygen or sulfur; R1 represents a hydrogen atom, an unsubstituted alkyl group, an aryl group or an alkyl group that is substituted by one or more halogen atoms, an alkoxy or an alkylthio group, cycloalkyl groups, cycloalkylthio groups or heterocyclic groups; R2 represents an alkyl group substituted by at least a —COOR3 group, wherein R3 represents a hydrogen atom, or an alkyl group that is substituted or not by one or more halogen atoms, cycloalkyl groups, or heterocyclic groups; R4 and R5, identical or different, representing an alkyl group that is substituted or not by one or more halogen atoms, cycloalkyl groups, heterocyclic groups; or a pharmaceutically acceptable salt or a stereoisomer thereof.